TOXIC CEO ... SVP Sales Retiring







I heard BT is retiring, is he being pushed out by the delusional CEO?
Not surprised BT is leaving, CEO is more worried about having his pic on magazine covers. How many times can he be receive accolades for "empowerment", he is out of touch with reality, surrounded by cool aid drinking sycophants.
 












Was probably rage fired, idiot CEO is always throwing his toys out of his crib. 2 year old temper tantrum, no wonder great members of sales team that were loved left. Place won't be around in 5 years.
 












Best CEO was Aselage, don't blame him for retiring from this board, he's probably embarrassed to see his hard work and clean up turned to shit. Look at the Censa compound, acquired by PTC Therapeutics, likely to be first treatment for PKU. Dube sold off money making assets, because he has an IR guy as CFO now they dont have revenue to develop pegtabatinase. Sales for filspari piss poor. Gary Lyons needs to fire Dube and beg Aselage to come back again and fix this cluster fk.
 






Best CEO was Aselage, don't blame him for retiring from this board, he's probably embarrassed to see his hard work and clean up turned to shit. Look at the Censa compound, acquired by PTC Therapeutics, likely to be first treatment for PKU. Dube sold off money making assets, because he has an IR guy as CFO now they dont have revenue to develop pegtabatinase. Sales for filspari piss poor. Gary Lyons needs to fire Dube and beg Aselage to come back again and fix this cluster fk.
Steve was the man! Never worked for such a well respected leader. I miss those days. EL Jefe, we miss the shit out of you! He and Lyons go way back to Genentech days, we need these two old bulls to fix this shit show.
 












July 1, 2021 — In its July issue published today, Life Science Leader Magazine featured our president and CEO Eric Dube. The feature piece, “How a First-Time CEO Transformed Retrophin Into Travere Therapeutics”, highlights Eric’s inspirational leadership journey, why Eric decided to join the company, his first 100 days as a new CEO, and the company’s transition from Retrophin to Travere Therapeutics.



Previous poster you r correct I counted 7 magazine covers, what a douche bag, lmao.